Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 11Terminated 2Unknown 1

Sponsor Class

OTHER 38INDUSTRY 16NIH 3NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Her2 Positive Metastatic Breast Cancer 1

Interventions

Radiotherapy 41Cisplatin 36Fluorouracil 17Paclitaxel 15Docetaxel 14Cyclophosphamide 14Carboplatin 14Filgrastim 13Doxorubicin 13Gemcitabine 11Etoposide 11Capecitabine 10Surgical Procedures, Operative 9Methotrexate 9Leucovorin 9Chemotherapy, Adjuvant 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Oxaliplatin 8Dexamethasone 7Bevacizumab 7Topotecan 6Radiotherapy, Conformal 6Prednisone 6Fenretinide 6Cetuximab 6Neoadjuvant Therapy 5Mitomycin 5Irinotecan 5Ifosfamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × NETWORK × Lapatinib × Clear all
NCT01123473 2016-10-12

Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Terminated
29 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01495884 2015-10-26

The Myocet/Lapatinib Study. ICORG 10-03, V5

Cancer Trials Ireland

Phase 1/2 Terminated
11 enrolled
Breast

Her2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡